- Home
- GILD vs CVS Comparison
GILD vs CVS Comparison
Compare GILD & CVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | CVS |
|---|---|---|
| Founded | 1987 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3B | 125.4B |
| IPO Year | 2003 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GILD | CVS |
|---|---|---|
| Price | $127.91 | $104.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | ★ $148.39 | $94.72 |
| AVG Volume (30 Days) | 7.8M | ★ 7.9M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | 2.55% | ★ 3.17% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | 1.61 | ★ 2.30 |
| Revenue | $24,689,000,000.00 | ★ $402,067,000,000.00 |
| Revenue This Year | $4.68 | $2.36 |
| Revenue Next Year | $6.04 | $4.69 |
| P/E Ratio | $76.82 | ★ $45.41 |
| Revenue Growth | ★ 9.98 | 7.85 |
| 52 Week Low | $107.75 | $58.50 |
| 52 Week High | $157.29 | $104.94 |
Technical Indicators
Market Signals| Indicator | GILD | CVS |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 69.13 |
| Support Level | $116.55 | $74.99 |
| Resistance Level | $126.81 | N/A |
| Average True Range (ATR) | 3.53 | 2.47 |
| MACD | 0.17 | 0.15 |
| Stochastic Oscillator | 45.06 | 79.00 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About CVS CVS Health Corporation
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.